Save information for later
Sign Up

Learn About Spinocerebellar Ataxia Type 2

What is the definition of Spinocerebellar Ataxia Type 2?

Spinocerebellar ataxia type 2 (SCA2) is a condition characterized by progressive problems with movement. People with this condition initially experience problems with coordination and balance (ataxia). Other early signs and symptoms of SCA2 include additional movement problems, speech and swallowing difficulties, and weakness in the muscles that control eye movement (ophthalmoplegia). Eye muscle weakness leads to involuntary back-and-forth eye movements (nystagmus) and a decreased ability to make rapid eye movements (saccadic slowing).

What are the causes of Spinocerebellar Ataxia Type 2?

Mutations in the ATXN2 gene cause SCA2. The ATXN2 gene provides instructions for making a protein called ataxin-2. This protein is found throughout the body, but its function is unknown. Ataxin-2 is found in the fluid inside cells (cytoplasm), where it appears to interact with a cell structure called the endoplasmic reticulum. The endoplasmic reticulum is involved in protein production, processing, and transport. Researchers believe that ataxin-2 may be involved in processing RNA, a chemical cousin of DNA. Ataxin-2 is also thought to play a role in the production of proteins from RNA (translation of DNA's genetic information).

How prevalent is Spinocerebellar Ataxia Type 2?

The prevalence of SCA2 is unknown. This condition is estimated to be one of the most common types of spinocerebellar ataxia; however, all types of spinocerebellar ataxia are relatively rare. SCA2 is more common in Cuba, particularly in the Holguín province, where approximately 40 per 100,000 individuals are affected.

Is Spinocerebellar Ataxia Type 2 an inherited disorder?

This condition is inherited in an autosomal dominant pattern, which means one copy of the altered gene in each cell is sufficient to cause the disorder. An affected person usually inherits the altered gene from one affected parent. However, some people with SCA2 do not have a parent with the disorder. Individuals who have an increase in the number of CAG repeats in the ATXN2 gene, but do not develop SCA2, are at risk of having children who will develop the disorder.

Who are the top Spinocerebellar Ataxia Type 2 Local Doctors?
Geriatrics | Internal Medicine
Geriatrics | Internal Medicine

Lehigh Valley Physician Group

798 Hausman Rd, Suite 220, 
Allentown, PA 
 (19.1 mi)
Languages Spoken:
English

David Carney is a Geriatrics specialist and an Internal Medicine provider in Allentown, Pennsylvania. Dr. Carney and is rated as an Experienced provider by MediFind in the treatment of Spinocerebellar Ataxia Type 2. His top areas of expertise are Hypertension, Glucocorticoid-Remediable Aldosteronism, Familial Hypertension, and Tracheitis.

Neurology | Psychiatry
Neurology | Psychiatry
2 Capital Way Ste 456, 
Pennington, NJ 
 (33.5 mi)
Languages Spoken:
English
Accepting New Patients

Charles Kososky is a Neurologist and a Psychiatrist in Pennington, New Jersey. Dr. Kososky and is rated as an Experienced provider by MediFind in the treatment of Spinocerebellar Ataxia Type 2. His top areas of expertise are Generalized Tonic-Clonic Seizure, Seizures, Multiple Sclerosis (MS), and Relapsing Multiple Sclerosis (RMS). Dr. Kososky is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
1205 Langhorne-newtown Rd. Suite #402, 
Langhorne, PA 
 (38.7 mi)
Languages Spoken:
English

James Gaul is a Neurologist in Langhorne, Pennsylvania. Dr. Gaul and is rated as an Experienced provider by MediFind in the treatment of Spinocerebellar Ataxia Type 2. His top areas of expertise are Benign Rolandic Epilepsy, Seizures, Memory Loss, and Essential Tremor.

What are the latest Spinocerebellar Ataxia Type 2 Clinical Trials?
A Phase 1 Placebo-Controlled Dose Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-ATXN2 in Adult Subjects With Spinocerebellar Ataxia Type 2

Summary: Adult participants with spinocerebellar ataxia type 2 (SCA2) who carry ≥33 cytosine, adenine, guanine (CAG) repeats in the ATXN2 gene, and who have met all protocol eligibility criteria will be randomized to receive a single dose of ARO-ATXN2 or placebo and be evaluated for safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) parameters.

Match to trials
Find the right clinical trials for you in under a minute
Get started
Who are the sources who wrote this article ?

Published Date: December 01, 2019
Published By: National Institutes of Health